Last reviewed · How we verify
NCT06104111: VitDPAS
Epigenetic Memory of Vitamin D Supplementation
Phase 1 trial testing Vitamin D3 in Immune System Diseases in 50 participants. Status unknown.
14 February 2024
Quick facts
| Lead sponsor | Polish Academy of Sciences |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 50 |
| Start date | 1 October 2023 |
| Primary completion | 14 February 2024 |
| Estimated completion | 30 March 2025 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Vitamin D3 (cholecalciferol) — full drug profile →
Conditions studied
- Immune System Diseases — all drugs for Immune System Diseases →
- Infections — all drugs for Infections →
- Healthy Lifestyle — all drugs for Healthy Lifestyle →
Sponsor
Polish Academy of Sciences — full company profile →
Who can join
Adults 18 to 65, any sex, with Immune System Diseases or Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators will study the mechanistic details of dietary programming of the epigenome at the example of epigenetic programming of primary human immune cells with the micronutrient vitamin D3. They will follow a small number of healthy adult volunteers individually over time while measuring per individual a large number of molecular and dynamic parameters that will be used for mechanistic modeling. The main hypothesis of the investigators is that nutritional components, such as vitamin D3, have a direct effect on the epigenome of the different cell types of the immune system. Using complementary in vivo, in vitro and in silico approaches, they will investigate the mechanistic basis of this dietary epigenetic programming process and how it creates memory.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
In vivo vitamin D targets reveal the upregulation of focal adhesion-related genes in primary immune cells of healthy individuals.
Ghosh Dastidar R, Jaroslawska J, Malinen M, Tuomainen TP, et al · · 2024 · cited 5× · PMID 39080417 · DOI 10.1038/s41598-024-68741-9 -
Transcriptomic profiling of immune modulation induced by vitamin D<sub>3</sub> in the VitDPAS and VitDHiD cohort studies.
Gospodarska E, Dastidar RG, Jaroslawska J, Rybiński M, et al · · 2025 · cited 2× · PMID 40389645 · DOI 10.1038/s41598-025-02495-w -
Chromatin and transcriptional dynamics underlying the immune-modulatory effects of vitamin D<sub>3</sub> in vivo.
Rybiński M, Ghosh Dastidar R, Zawrotna N, Gospodarska E, et al · · 2025 · cited 1× · PMID 41413700 · DOI 10.1038/s41598-025-32831-z
Verify or expand the search:
- PubMed search for NCT06104111
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Vitamin D3
Trials testing the same drug.
- NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
- NCT07460336 — Effects of Cofrogliptin on Beta-Cell Function in LADA Patients · NA · not yet recruiting
- NCT07006714 — Preoperative Correction of Vitamin D Deficiency in Total Joint Arthroplasty (TJA) · Phase 4 · active not recruiting
- NCT07269223 — Oral Vitamin D3 Effect on Inflammatory Biomarkers in Ulcerative Colitis Patients · NA · recruiting
- NCT07048860 — ICOPE INTENSE-K Pilot Study · NA · recruiting
Other recruiting trials for Immune System Diseases
Currently open trials in the same condition.
- NCT06575426 — A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes M · Phase 1, PHASE2 · recruiting
- NCT06353087 — Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry) · recruiting
- NCT06271252 — A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · Phase 1 · recruiting
- NCT06353035 — Biodiversity Interventions for Well-Being · NA · active not recruiting
- NCT04656873 — Immuno-Oncology Database and Bioregistry · active not recruiting
Other Polish Academy of Sciences trials
Trials by the same sponsor.
- NCT06603922 — The Personalized Psychological Treatment for Psychosis · NA · not yet recruiting
- NCT05971992 — INulin-type Fructans-induced Gut Microbiota Modulation Impact on GUT-SKIN Axis Parameters in Psoriasis · NA · completed
- NCT05652972 — Effect of KETOgenic Diet on Metabolism, Inflammation, Nutrition Deficiencies and OXidative Stress in Women With Overweig · NA · unknown
- NCT03064997 — Prebiotic as a Supplement of Gluten-free Diet in the Management of Celiac Disease in Children · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06104111 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Polish Academy of Sciences
- Last refreshed: 27 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06104111.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing